세계의 웨어러블 주사기 시장 보고서 : 유형, 기술, 용도, 최종 용도, 지역별(2024-2032년)

The global wearable injectors market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.4 Billion by 2032, exhibiting a growth rate (CAGR) of 13.4% during 2024-2032. The market is experiencing significant growth driven by increasing prevalence of chronic diseases, growing focus on personalized medicine, heightening healthcare costs that incentivize the adoption of wearable injectors for efficient drug delivery, rising preference for home-based treatment options, rapid expansion of biopharmaceutical pipeline, and ongoing technological advancements.

Wearable Injectors Market Analysis:

Major Market Drivers: The rising scope of chronic diseases treatments and the necessity for more targeted and effective drug delivery methods are propelling the market growth. Ongoing technological advancements in wearable injection devices due to better usability and customization features that have become popular for patients and healthcare workers are fueling market growth.

Key Market Trends: There is a growing trend to develop injectors with wearable devices equipped with additional features like dose control and self-drug delivery, thereby improving patient convenience and therapy compliance. Apart from that, the emergence of injectors combining with digital health platforms and mobile applications is contributing to the advancement of remote patient monitoring, real-time data collection, and personalized healthcare delivery, thus fueling market growth.

Geographical Trends: Among the regions, North America is the leading market for wearable injectors primarily because of the existence of major industry players, cutting- edge technology and the high adoption rate of advanced healthcare technology. The market is experiencing substantial growth in Europe owing to the set of infrastructural factors like preferential regulatory framework, rising healthcare investment, and growing awareness around self-administration devices.

Competitive Landscape: Some of the major market players in the wearable injectors industry include Becton Dickinson and Company, CeQur SA, Debiotech SA, Dexcom Inc., Enable Injections Inc., Gerresheimer AG, Insulet Corporation, Tandem Diabetes Care Inc., West Pharmaceutical Services Inc., Ypsomed AG., among many others.

Challenges and Opportunities: The market faces challenges such as the complexity of regulation and challenges with reimbursement whereas it also offers opportunities in transition to patient-centeredness. Financial limitations and long-term clinical evidence are also one of the major barriers to market expansion.

Wearable Injectors Market Trends:

Increasing prevalence of chronic diseases

The rising incidence of chronic illnesses across the globe (diabetes, cancer, and cardiovascular disorders), is the main stimulator of the injector market. Providing the long-term are those conditions that need full time medication management, and this is the wearable injectors come to offer a simple and effective solution to patients who can simply administer their medications without hassle and consistency. The rise in chronic diseases' prevalence leads to demand growth in a wearable injectors segment. These injectors provide patients with the convenience of managing their health conditions anywhere anytime. For instance, as per the NATIONAL LIBRARY OF MEDICINE (NLM), nearly half of all Americans suffer from at least one chronic disease, with approximately 133 million individuals affected. This data illustrates the increasing workload of chronic diseases for healthcare system and illustrates the pressing need for powerful management actions, among them the successful incorporation of latest solutions such as administrable injectors in order to improve patients' outcome and lifestyle.

Ongoing technological advancements:

The ongoing advancements in wearable injector technology promote completely new drug delivery methods and fuels industry growth. Wearable technologies comprise of features such as connectivity with mobile devices, dose monitoring capability, and automatic drug delivery mechanisms, which eventually improve the experience and adherence to the treatment from the user's perspective. Along with more user-friendly, compact, and intelligent injectors emerging, they are gaining more acceptance by a variety of people, while healthcare providers are being able to utilize them to formulate more individualized and accurate drug delivery systems. The direct administration of wearable injectors to digital health platforms increases the efficiencies of the system even more, making out-of-touch checkups, and data-driven health-management possible to use. For instance, according to the NATIONAL INSTITUTE OF HEALTH (NIH), in the US, there was a 154% increase in telehealth usage in the first quarter of 2020, with 80% of all respondents accessing care via telemedicine in 2022, up from 72% in 2021.

Growing preference for home-based treatment options:

The transition toward home-based healthcare due to the rapid shift to patient-centered health care and portability of injectors as an attractive alternative to clinic-based treatments is fueling market growth. The U.S. home healthcare market projected compound annual growth rate (CAGR) of 7.4 % from 2024 to 2032 as per the report published by IMARC GROUP. Patients really value the self-administration of medications that are convenient and allow them to do so at home, witnessing the positive effect on their health in real-time. Chronic disease management requires ongoing treatment regime adherence; therefore, this trend is especially prominent in those cases. Wearable injectors play an increasingly more important role in the healthcare system, as they allow patients to take control of their treatment outcomes, which helps save healthcare costs while also improving the patients' satisfaction.

Wearable Injectors Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, technology, application, and end use.

Breakup by Type:

On-body

Off-body

On-body accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes on-body and off-body. According to the report, on-body represented the largest segment.

The on-body type of wearable injectors in the market is primarily driven by its convenience, ease of use, and potential for improved treatment adherence. These devices are designed to be worn directly on the body, providing patients with a discreet and hands-free solution for medication delivery. By eliminating the need for manual injections and offering customizable dosing schedules, On-body wearable injectors empower patients to conveniently self-administer medications without interrupting their daily activities. Additionally, the integration of advanced features such as dose monitoring and connectivity enhances patient engagement and allows for remote monitoring by healthcare providers, further driving the adoption of On-body wearable injectors in the market. For instance, MEDTRONIC launched an infusion set in April 2021 that allows for the transport of insulin from the pump to the body, showcasing advancements in on-body wearable injector technology. This innovation doubles the length of time an infusion set can be worn so that patients can safely continue on insulin pump therapy with fewer interruptions and insertions while also enjoying greater convenience and comfort in their diabetes management routine.

Breakup by Technology:

Spring-based

Motor-driven

Rotary Pump

Expanding Battery

Others

Spring-based holds the largest share of the industry

A detailed breakup and analysis of the market based on the technology have also been provided in the report. This includes spring-based, motor-driven, rotary pump, expanding battery, and others. According to the report, spring based accounted for the largest market share.

The spring-based principle of wearable injectors is established by its well-known feature of simplicity, reliability, and affordability. These medications are dispensed using spring-type mechanical mechanisms that make them independent on complex electronics or power sources. This elimination does reduce the production costs and improves the resistance and reliability of the wearable injectors such that they are applicable for long term use. Moreover, the perfect precision and certainty of spring injectors in the delivery of the drugs, eliminates drug level errors and maximizes the therapeutic outcome of patients. The devices stand out from the perspective of both patients and health care providers due to their simple design and long-term proven results as spring-base wearable injectors. For instance, BECTON DICKINSON (U.S.-based company) is a well-known innovator, and the spring-based injector offered by BD (Libertas) is one such innovation. This advanced drug delivery system is a unique spring-based power generator that saves batteries or eliminates the removal of heavy metals through discharge.

Breakup by Application:

Oncology

Infectious Diseases

Cardiovascular Diseases

Autoimmune Diseases

Others

Oncology represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the application. This includes oncology, infectious diseases, cardiovascular diseases, autoimmune diseases, and others. According to the report, oncology represented the largest segment.

The rising adoption of wearable injectors in oncology is attributed to the increasing requirements for patients to be comfortable and convenient, and to adhere to the treatment programme. Most individuals battling with oncology diseases (cancer) are often expected to take the chemotherapy drugs for long periods and in frequent doses; a situation that is both physically and emotionally exhausting. Approximately 1,806,590 new cancer cases were diagnosed, and 606,520 deaths caused by cancer happened in the USA in the year of 2020 alone as stated by the NATIONAL CANCER INSTITUTE. Prostate cancer, lung cancer, and colon cancer are the leading types, followed by other cancer types, taking up a significant percentage of new cancer diagnoses. Wearable injectors can offer a user-friendly solution by ensuring the drug is continuously and controlled delivered for patients and allowing them to receive their treatments outside the hospital environment, such as patients with cancer whose IVs will run for hours. Patients' quality of life, besides improving also facilitates treatment adherence which enables patients to take their medications regularly; hence they have better outcomes from these anti-cancer measures.

Breakup by End Use:

Hospitals and Clinics

Home Care

Others

Home care exhibits a clear dominance in the market

A detailed breakup and analysis of the market based on the end use have also been provided in the report. This includes hospitals and clinics, home care, and others. According to the report, home care accounted for the largest market share.

The growing trend of home care settings for the use of wearable injectors is notable among the patient-centric healthcare delivery techniques and the increasing demands for the use of easy and cost-effective treatment approaches. Personal assistance, which enables patients to control medical conditions in a home environment, provides comfort and autonomy. Wearable injectors come in handy as they help with self-administration of drugs, which prevents a patient from having to keep hospital visits due to the nature of his/her treatment. Moreover, injector devices that incorporate dose monitoring and connectivity equipment constitute another innovation in wearable technology which has important implications for the sense of security the patient can feel and enables remote monitoring by healthcare providers, only which further increase their popularity in home care.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest wearable injectors market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for wearable injectors.

The major players in the North American cannula injectors market are mainly due to its most sophisticated healthcare system in the world with the highest per capita healthcare spending, thus making it easy for innovative medical technologies to be widely embraced. Moreover, growing chronic diseases and an aging population posing the challenge of convenient and efficient drug delivery solutions result in an increased demand for wearable injectors. And lastly, the presence of market players with authority and technological evolution creates a requirement for growth and innovation of the market. Moreover, there is an availability of favorable reimbursement policies and conducive regulatory atmosphere which offers an extra boost for acceptance of wearable injectors in North America contributing to the global wearable injectors market. For instance, United States wearable injectors market size is exhibited to grow at a rate (CAGR) of 5.30 % during 2024-2032 as per the reports published by the IMARC GROUP.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the wearable injectors industry include Becton Dickinson and Company, CeQur SA, Debiotech SA, Dexcom Inc., Enable Injections Inc., Gerresheimer AG, Insulet Corporation, Tandem Diabetes Care Inc., West Pharmaceutical Services Inc. and Ypsomed AG.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The key players of wearable injectors market are innovating to further improve the features and understand the changing needs of the patients. Some of the latest innovations include the emergence of smart wearable injectors that come with high-end features such as connectivity, dose sensing and auto-driving among others. Moreover, many companies have already come up with wearable injectors which have Bluetooth connectivity that enables patients to monitor their medication intake and receive a reminder through their phones. Furthermore, the miniaturization and design advancements have resulted in the development of less conspicuous and more comfortable wearable injectors which have a positive impact on the acceptance and compliance with the treatment among patients. These innovations highlight the efforts of key players to provide clutter-free products that cater for the lifestyle of patients and therapeutic outcomes.

Wearable Injectors Market News:

Feburary 16, 2023: Insulet Corporation acquired the assets of Automated Glucose Control LLC (AGC), a company focused on developing and commercializing automated insulin delivery technology, showcasing their commitment to innovation in the wearable injectors sector.

March 17, 2023: Tandem acquired infusion set developer, Capillary Biomedical, indicating their strategic moves in the wearable injectors market. This indicates that Tandem is constantly aiming for innovation and growth by supplying its products to medical devices. Tandem's acquisition of Capillary Biomedical enables its infusion set technology, which it incorporated with its line of wearable injector solutions, thus empowering its stand in the industry.

Key Questions Answered in This Report:

• How has the global wearable injectors market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global wearable injectors market?
• What is the impact of each driver, restraint, and opportunity on the global wearable injectors market?
• What are the key regional markets?
• Which countries represent the most attractive wearable injectors market?
• What is the breakup of the market based on the type?
• Which is the most attractive type in the wearable injectors market?
• What is the breakup of the market based on technology?
• Which is the most attractive technology in the wearable injectors market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the wearable injectors market?
• What is the breakup of the market based on the end use?
• Which is the most attractive end use in the wearable injectors market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global wearable injectors market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Wearable Injectors Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 On-body
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Off-body
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Spring-based
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Motor-driven
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Rotary Pump
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Expanding Battery
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Application

• 8.1 Oncology
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Infectious Diseases
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Cardiovascular Diseases
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Autoimmune Diseases
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by End Use

• 9.1 Hospitals and Clinics
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Home Care
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Becton Dickinson and Company
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 CeQur SA
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Debiotech SA
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Dexcom Inc.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Enable Injections Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Gerresheimer AG
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
  • 15.3.7 Insulet Corporation
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Tandem Diabetes Care Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
  • 15.3.9 West Pharmaceutical Services Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
  • 15.3.10 Ypsomed AG
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis